Navigation Links
Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
Date:1/3/2008

NEW YORK, Jan. 3 /PRNewswire/-- Intercept Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases, today announced the appointment of Luciano Adorini, M.D., to the newly created position of Chief Scientific Officer. Dr. Adorini brings over 20 years of experience in therapeutic research and development, recently serving as Chief Scientific Officer at BioXell (SWX: BXLN), a biopharmaceutical company which he co-founded.

Mark Pruzanski, M.D., Founder, President and CEO of Intercept Pharmaceuticals, commented, "Luciano's proven R&D leadership will be invaluable as we continue to advance our pipeline of first-in-class compounds and expand our focus beyond chronic liver diseases to other indications involving progressive organ damage that results from some combination of chronic inflammation, fibrosis and metabolic dysfunction."

During Dr. Adorini's tenure at BioXell, he was responsible for advancing a broad pipeline of products in multiple disease indications. Prior to this, he served as Associate Director of Roche Milano Ricerche, where he contributed to the development of several drugs. Earlier in his career, Dr. Adorini was research director of a unit at the Preclinical Research Center, Sandoz Pharma, Ltd., in Basel.

Dr. Adorini has authored over 240 journal articles and other scientific publications, becoming a highly cited researcher in Immunology, with a focus on immunosuppressive and immunoregulatory mechanisms in the treatment of inflammatory and autoimmune diseases. He is a board member of a number of peer-reviewed publications and is currently serving as president of the Italian Society of Immunology, Clinical Immunology and Allergology. Dr. Adorini received his M.D. degree from the Medical School of Padova University and conducted postdoctoral studies at the University of California at Los Angeles.

About Intercept Pharmaceuticals

New York City-based Intercept Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing small molecule drugs for the treatment of chronic liver and metabolic diseases. Since 2002, Intercept researchers have published extensively on the key role of the farnesoid X receptor (FXR) as a regulator of bile and cholesterol metabolism in the liver, with preclinical data from numerous studies providing strong rationale for the advancement of FXR agonists as hepatoprotective therapeutics in chronic liver disease. The Company intends to lead in the advancement of drug candidates acting on FXR and other bile acid receptors and is developing a pipeline of novel lead compounds for multiple indications. For more information on Intercept Pharmaceuticals, please visit the Company's website at http://www.interceptpharma.com .


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... 22, 2017 , ... RURO, Inc., a leading LIMS, RFID, ... content-packed update to the Limfinity® framework. , LimitLIS® and other RURO solutions based ... of customers among labs and other businesses. Limfinity® 6.5 adds new features and ...
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., a ... announce the issuance of a new patent covering a ... by the U.S. Patent and Trademark Office on May ... of the Buzz of Bio award in 2014 in ... to developing non-drug approaches to chronic disease. Renadyl™, the ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... clinical development reported today that it is launching two new additions of its ... be demonstrating new capabilities at the DIA 2017 Annual Meeting in Chicago, IL, ...
(Date:6/16/2017)... ... June 16, 2017 , ... CTNext , Connecticut’s ... Awards (EIA), held at The LOFT at Chelsea Piers in Stamford. , Nine finalists, ... a panel of judges for an opportunity to secure $10,000 awards to help support ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):